NOVAVAX

[dothedd]

Creating Tomorrow’s Vaccines Today
www.novavax.com/

2005:

August 9, 2005

Novavax Announces New President, CEO and Board Member

MALVERN, PA, Aug. 9 /PRNewswire-FirstCall/ - Novavax, Inc. (Nasdaq: NVAX), a specialty biopharmaceutical company, announced Dr. Rahul Singhvi has been appointed President and CEO of Novavax effective today. He has also been elected a director of the Company. Dr. Singhvi's appointment follows the decision of Nelson M. Sims to retire immediately from his position as President, CEO and Director of Novavax.

"During the last year, Novavax has continued to make significant progress in the development of new micellar nanoparticle (MNP) based products, including non-hormone compounds. The implementation of a rigorous target selection and product development process, instituted by Dr. Singhvi, has enabled the Company to expand its pipeline to ten new products within attractive markets," said Gary C. Evans, Chairman of the Board of Directors of Novavax. "The Board has been most impressed by Dr. Singhvi's contributions since he joined the Company in April, 2004. Dr. Singhvi's broad scientific experience within the pharmaceutical industry makes him an excellent choice to lead the Company into our planned new product development focus. Separately, the Board wishes Nelson Sims and his family the best and thanks him for his past contributions including the revamping of the Novavax management team."

Dr. Rahul Singhvi, President and CEO of Novavax, Inc. commented, "I joined Novavax because of its innovative drug delivery and vaccine technologies. By coupling the strength of our proprietary technologies with our manufacturing capabilities, Novavax is in a position to advance and grow our pipeline. Our
management team is excited about the opportunities that exist within this Company. Our job is to now convince the marketplace why we are so excited."

Prior to joining Novavax in 2004, Dr. Singhvi had eleven years of extensive experience in the pharmaceutical industry, including serving as a Director within the manufacturing division of Merck & Company. Dr. Singhvi holds Master and Doctorate of Science degrees in Chemical Engineering from MIT and a Master of Business Administration from The Wharton School.

In addition to the appointment of Dr. Singhvi, the Company has appointed Mr. Raymond J. Hage Jr. as Senior Vice President and Chief Operating Officer. Most recently Mr. Hage served as Vice President of Corporate Development of Novavax.

About Novavax, Inc.

Novavax, Inc. is a specialty biopharmaceutical company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets.


8-Dec-2005
Other Events

Item 8.01 Other Events.
Novavax, Inc. has created a new Government Relations Committee of the Board of Directors to assist the company with respect to the development and funding of its on-going avian flu and seasonal flu vaccine programs. John O. Marsh, Jr., former Congressman, Counselor (with Cabinet rank) to President Gerald Ford and Secretary of the Army, is Chairman of the new committee, which is comprised of four members. Through the assistance of the committee and legal counsel and third party consultants retained by the committee, Novavax has met with numerous members of the U.S. House of Representatives and Senate and their staff over the past several weeks.

The purpose of the committee is to monitor legislative and regulatory initiatives and guide management of the company in pursuing research and development funding specifically relating to vaccines as well as the company’s other current and future products and product development efforts. The committee also will be responsible, among other things, for assisting management of the company in communicating, working with and educating local, regional and national legislators and regulators on the efforts of, and issues of interest to, Novavax.


DEPARTMENT OF DEFENSE APPROPRIATIONS CONFERENCE REPORT FAVORABLE TO FUNDING
NOVAVAX’ FLU VIRUS-LIKE PARTICLE VACCINE TECHNOLOGY
library.corporate-ir.net/library/71/711/71178/items/178704/010606RodmanRenshawResearchReportNVAXDoDAppropriations.pdf



2010:
Research and Development - www.novavax.com/go.cfm?do=Page.Vi...
Manufacturing - www.novavax.com/go.cfm?do=Page.Vi...
H1N1 - www.novavax.com/go.cfm?do=Page.Vi...
Recent Releases: www.novavax.com/go.cfm?do=Page.Vi...
NOVAVAX TO THE WORLD - www.novavax.com/go.cfm?do=Page.Vi...

All in five short years!

[sanityjones]

Is this where I get my online swine flu vaccination? I'm not sure which key I need to push..........hello. Anybody there?..........................hello??

[diverdown34]

sanity be nice to her or she will bite your head off

[chiver78]

what I want to know is, how did she create a new forum for this spam?

[diverdown34]

she asked and I created a board for her

[sanityjones]

No disrespect intended, in fact I am completely fascinated by the emergence of the swine flu and am very interested to know more about it. If you will recall we had quite the spirited discussion on this very matter on the MSN P&M board last fall. Perhaps this site will be of service in arming us all with the knowledge and support we need in order to both understand and combat this form of influenza. Thank you very much for your contribution to this board, I expect it will generate a lot of discussion.

sanityjones

[dothedd]

Dec 27, 2010 21:27:17 GMT -5 @sanityjones said:

Is this where I get my online swine flu vaccination? I'm not sure which key I need to push..........hello. Anybody there?..........................hello??

I believe you would be better served at your local pharmacy. However, if you want to wait in line ... it will be a very, very long wait!

[diverdown34]

Sanity I am just pulling ur leg...... Meet dothedd or barb as we call her on the board....... she could probably tell you whatever you want to know about NVAX and N1H1, she has been tracking it for years and will be bringing a wealth of information from the MSN board

[dothedd]

Dec 27, 2010 21:41:23 GMT -5 @sanityjones said:

No disrespect intended, in fact I am completely fascinated by the emergence of the swine flu and am very interested to know more about it. If you will recall we had quite the spirited discussion on this very matter on the MSN P&M board last fall. Perhaps this site will be of service in arming us all with the knowledge and support we need in order to both understand and combat this form of influenza. Thank you very much for your contribution to this board, I expect it will generate a lot of discussion.

sanityjones

SJ:
NOVAVAX to the rescue, we hope.

[dothedd]

Dec 27, 2010 21:48:00 GMT -5 diverdown34 said:

Sanity I am just pulling ur leg...... Meet dothedd or barb as we call her on the board....... she could probably tell you whatever you want to know about NVAX and N1H1, she has been tracking it for years and will be bringing a wealth of information from the MSN board

Diver,

The bottom line is that H1N1 and H5N1 are mutating. There is no easy answer. I have been cross referencing information since 2005 and posting to the other board since 2008.

I suggest reading some of the threads on the MSN NVAX BOARD before it is deleted to glean an understanding of the subject matter. moneycentral.msn.com/community/message/board.asp?symbol=NVAX&BoardID=524

[diverdown34]

I hope u bring some of the stuff you posted on that board over here before it is deleted forever barb

[dothedd]

Diver:

I am getting ready to leave town after New Year’s. However, I am downloading as much relative information from the old board to post when I return.

Do you have specific threads in mind?

barb

[Sammy]

Hi Barb! Good to see you.

[dothedd]

Greetings, Baby Cakes:

Hope your HOLIDAY was MERRY! I'm sure it was WHITE!

[Sammy]

Oh baby, it's been white on white on white on......... There is 19 inches of snow on the ground outside my home. I'm already tired of the Winter Wonderland look.

How have you been??

[dothedd]

Baby Cakes:

If you recall, a few years ago I offered to loan you my "Bobcat" ... I haven't needed it [pause] this year, but winter has just begun.

I'm doing great after a tumultuous three years of passing family members. I'm off to the slopes again in a couple of weeks ... after years of not being able to leave town.

Life is good!

[tyfighter3]

Barb, glad to see you over here.

[dothedd]

HI Ty:

I decided to give up posting on message boards after MSN announced that they were shutting down their stock boards; however, in retrospect, I believe Novavax has a story to tell ... so here I am.

We need to find another NOG!

HAPPY NEW YEAR!

barb

[dothedd]

Dec 27, 2010 22:21:33 GMT -5 diverdown34 said:

I hope u bring some of the stuff you posted on that board over here before it is deleted forever barb

MEINE SACHEN, won't transfer. Hopefully, I can solve the problem ... SOON!

[cronewitch]

What is Novavax? Do we need to know?

[dothedd]

CW:

I am on a time line to transfer 2+ years of work from the MSN NVAX Board to this new board before the other board is shut-down forever.

Briefly, here is an explanation from Novavax's Website: "Novavax, Inc. is a clinical stage biopharmaceutical company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The Company produces potent VLP-based, recombinant vaccines utilizing new and efficient manufacturing approaches.

Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of pandemic influenza including H1N1 and H5N1 influenza, as well as seasonal flu, Respiratory Syncytial Virus (RSV) and Varicella Zoster Virus (VZV). We have validated our approach in animals and are now in clinical testing with our pandemic and seasonal influenza vaccines.

Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, our long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.

Novavax plans to apply its VLP-based vaccine approach to other viral diseases beyond influenza."

My particular interest in Novavax is that its vaccines are formulated without ADJUVANTS/PRESERVATIVES, as well as, the time frame of the manufacturing process to product.

Novavax's approach makes it possible to produce vaccine within 10 to 12 WEEKS of new viral strain identification with high yields, verses 8 to 10+ MONTHS for egg vaccines experiencing as much as 30% loss of product due to contamination.

Peruse the website Manufacturing link and note the difference.

That's the short of it!

Yes, in my opinion it is worth your time and effort to investigate Novavax, because of its importance and relevance to the future of all vaccine manufacturing, and also as a consideration for a short or long-term investment.

When I have completed "MY TASK", and when I return from vacation, I will be available to devote time chatting about Novavax.

Until then, I wish you a VERY HAPPY NEW YEAR.

DOTHEDD

My suggestion is to start at HOME and read to the end of MEDIA.
www.novavax.com/ IT IS FASCINATING!

DISCLOSURE: I am a Novavax Shareholder

[dothedd]

NOVAVAX Launches Phase I Clinical Trial to Evaluate its Novel Vaccine Against Respiratory Syncytial Virus (RSV)
Vaccine candidate targets world’s leading cause of infant death and childhood respiratory disease ...

Rockville, MD – January 4, 2011 – Novavax, Inc. (Nasdaq: NVAX) announced today that it has begun patient enrollment in a Phase I clinical trial to assess the safety, immunogenicity and tolerability of a vaccine candidate against respiratory syncytial virus (RSV). In this blinded, placebo-controlled, escalating-dose study of healthy adults 18 to 49 years old, a total of 100 subjects will be allocated to four cohorts and randomized to receive vaccine treatment or saline placebo in a 4:1 ratio. It is expected that interim top-line data from the trial will be available in the third quarter of 2011.

Remarking on this key accomplishment for the Company, Dr. Rahul Singhvi, Novavax’s President and CEO, said, “The launch of this trial is timely because there are no vaccines currently approved for RSV disease, which is the most important viral cause of lower respiratory tract infection in infants and children worldwide and is a major cause of respiratory illness in elderly adults. The initiation of the trial for this RSV vaccine candidate marks a key milestone for Novavax, as the Company now has a clinical candidate in a second major disease target in addition to influenza.”

Novavax has evaluated its RSV vaccine candidate in well-accepted animal models of toxicity and disease and found it to be safe at all doses tested. Preclinical results have shown induction of neutralizing antibodies and protection from RSV challenge with no disease enhancement and no detection of disease in any of the animals immunized with the vaccine at any dose level tested. Novavax’s vaccine uses highly purified recombinant particles of RSV-F fusion protein normally found in the virus.

About Respiratory Syncytial Virus

RSV is the most important viral cause of lower respiratory tract infection in infants and children worldwide. The global disease burden is estimated at 64 million cases and 160,000 deaths every year. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. Each year, 75,000 to 125,000 children in this age group are hospitalized due to RSV infection. Almost all children will have had an RSV infection by their second birthday. When infants and children are exposed
to RSV for the first time, 25% to 40% of them have signs or symptoms of bronchiolitis or pneumonia, and 0.5% to 2% will require hospitalization. Most children hospitalized for RSV infection are under 6 months of age. Additionally, wheezing illnesses caused by RSV, particularly those severe enough to lead to hospitalization, are associated with an increased risk of asthma at school age.

It is also estimated that more than 8.5 million adults, including the elderly over age 65 years, are infected and 900,000 patients are hospitalized annually due to RSV infection in the United States and major European countries. In the United States alone there are 177,500 hospitalizations among high-risk adults resulting in annual medical costs exceeding $1 billion. There is currently no approved vaccine for the prevention of RSV.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website: www.novavax.com


January 04, 2011 08:10 ET (13:10 GMT)
News for 'NVAX' - (*DJ Novavax Began Enrollment Of Phase I Trial For RSV Vaccine Candidate)

January 04, 2011 08:10 ET (13:10 GMT)
News for 'NVAX' - (*DJ Novavax Expects Interim Top-Line Data From Trial Will Be Available In 3Q >NVAX)

[dothedd]

Jan 4, 2011 21:38:27 GMT -5 @franktheimpaler said:

Hows my sweet whipster?

A wild day today on the Market Talk board...I barely escaped with my life for being......................................correct!

I will come and vist you if you come and vist me...what do you say?

Frank, Darlin:

I’m kind of busy right now downloading one page at a time of threads I want to save from the old board before they turn-the-lights-out PERMANENTLY, as well as, getting ready to leave town.

However, I will check in, when possible the next couple of weeks, but you can count on me as a regular when I return.

HAPPY 2011!

[dothedd]

RSV

Jan 05, 2011 (Datamonitor via COMTEX) -- Novavax, Inc., a clinical-stage
biopharmaceutical company, has initiated patient enrollment in a Phase I
clinical trial to assess the safety, immunogenicity and tolerability of a
vaccine candidate against respiratory syncytial virus, or RSV.

In this blinded, placebo-controlled, escalating-dose study of healthy adults 18
to 49 years old, a total of 100 subjects will be allocated to four cohorts and
randomized to receive vaccine treatment or saline placebo in a 4:1 ratio. It is
expected that interim top-line data from the trial will be available in the
third quarter of 2011.

Novavax has evaluated its RSV vaccine candidate in well-accepted animal models
of toxicity and disease and found it to be safe at all doses tested. Preclinical
results have shown induction of neutralizing antibodies and protection from RSV
challenge with no disease enhancement and no detection of disease in any of the
animals immunized with the vaccine at any dose level tested. Novavax's vaccine
uses highly purified recombinant particles of RSV-F fusion protein normally
found in the virus.

Remarking on this key accomplishment for the Company, Dr Rahul Singhvi,
Novavax's President and CEO, said, "The launch of this trial is timely because
there are no vaccines currently approved for RSV disease, which is the most
important viral cause of lower respiratory tract infection in infants and
children worldwide and is a major cause of respiratory illness in elderly
adults. The initiation of the trial for this RSV vaccine candidate marks a key
milestone for Novavax, as the Company now has a clinical candidate in a second
major disease target in addition to influenza."

[dothedd]

IN THE NEWS:

NOVAVAX Launches Phase I Clinical Trial to Evaluate its Novel Vaccine Against Respiratory Syncytial Virus (RSV)

NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate

NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial


BioPharm International October 2010 - Release and Stability Testing Programs for a Novel Virus-Like Particle Vaccine

www.novavax.com/

[dothedd]

The February-March event lineup. 26-Jan-11 07:32 pm
13th Annual BIO CEO & Investor Conference
New York, NY
February 14-15, 2011
Presenter: Dr. Rahul Singhvi

6th Latin America Clinical Trials Conference
Miami, FL
March 1–2, 2011
Examination of a Clinical Trial Conducted in Mexico City which Enrolled 4,550 Subjects During the Pandemic of 2009 Preventing the Spread of H1N1
Keynote Speaker: Kathy Lenhard

2011 Citi Global Healthcare Conference
New York, NY
March 1–3, 2011
Speaker: Dr. Rahul Singhvi

Roth Growth Stock Conference
Dana Point, CA
March 13 – 16, 2011
Presenter: Dr. Rahul Singhvi
Webcast: click here.


BIT Life Sciences’ 3rd Annual World
Vaccines
Congress-2011
(WCV-2011)

Time: March 23 - 25, 2011 Venue: Beijing, China

March 23, 2011

10:30-10:55

Title: Commercialization Strategies for Vaccines in the Emerging Markets

Dr. Rahul Singhvi, CEO & President, Novavax Inc., USA

[dothedd]

Andrea Bocelli - Por Ti Volare (Para mi bebita)

[dothedd]

(WO/2011/011390) PURIFIED RECOMBINANT INFLUENZA VIRUS

HA PROTEINSBiblio. DataDescriptionClaimsNational PhaseNoticesDocumentsLatest bibliographic data on file with the International Bureau

Permanent LinkBookmark this page
--------------------------------------------------------------------------------

Pub. No.: WO/2011/011390 International Application No.: PCT/US2010/042568
Publication Date: 27.01.2011 International Filing Date: 20.07.2010
IPC: C12N 7/02 (2006.01), C07K 1/14 (2006.01), C07K 1/16 (2006.01), C07K 1/18 (2006.01), C07K 1/22 (2006.01), C07K 1/34 (2006.01), C07K 1/36 (2006.01)

Applicants: NOVAVAX, INC. [US/US]; 9920 Belward Campus Drive

Rockville, Maryland 20850 (US) (All Except US).
SMITH, Gale [US/US]; (US) (US Only).
PINCUS, Steven [US/US]; (US) (US Only).
Inventors: SMITH, Gale; (US).PINCUS, Steven; (US). Agent: TUSCAN, Michael S.; Cooley LLP 777 6th Street, N.W. Suite 1100 Washington, District of Columbia 20001 (US) .
Priority Data: 61/226,994 20.07.2009 US

Title: PURIFIED RECOMBINANT INFLUENZA VIRUS HA PROTEINS
Abstract: Disclosed is a purified viral protein and/or VLPs with high purity and high vaccine potency, and methods of purifying thereof Further disclosed are uses of the purified viral protein and/or VLPs as a standard in a vaccine potency assay

Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)

IN SUMMARY: " The new invention can be used to produce VLP vaccines with better HA (more antigenic), and the method worked in all situations, and also from the drawing board all the way to vaccination and protection of humans. The whole patent can be summarized as follows: The HA protein in our flu VLP's are now better purified, and therefore more antigenic. This was proven for all situations and combinations you could think of."

[dothedd]

VP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials

Rockville, MD (February 9, 2011)–/PRNewswire-FirstCall/-Novavax, Inc. (NASDAQ:NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at the WHO headquarters in Geneva, Switzerland where Dr. Glenn will be part of a session entitled: “Pandemic and Potentially Pandemic Vaccines Developed Using New Technologies.” Dr. Glenn’s presentation is entitled: “Rapid Response during the 2009 (H1N1) Pandemic in Mexico with an Influenza VLP Vaccine.” The presentation will be available at www.novavax.com under the Investors/Events tab after the event.

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs it’s cutting edge technology to create next generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary VLP technology and unique disposable system enables rapid vaccine development and production where and when it’s needed, worldwide. For more information about Novavax, please visit www.novavax.com.


www.novavax.com/

[dothedd]

13th Annual BIO CEO & Investor Conference
New York, NY
February 14-15, 2011
Presenter: Dr. Rahul Singhvi

Webcast:

www.veracast.com/webcasts/bio/ceoinvestor2011/92207297.cfm